Navigation Links
Alseres Pharmaceuticals, Inc. to Present at Windhover's Therapeutic Area Partnerships Conference
Date:10/18/2007

HOPKINTON, Mass., Oct. 18 /PRNewswire-FirstCall/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that Dr. Frank Bobe, Executive Vice President and Chief Business Officer of Alseres Pharmaceuticals, Inc., will be presenting at Windhover Information's 2nd Annual Therapeutic Area Partnerships in Philadelphia, PA October 24-26, 2007. Dr. Bobe will be presenting an overview on Alseres Regenerative Therapeutics program. Cethrin(R), the Company's lead regenerative therapeutic for acute spinal cord injury, was named one of the "Top 10 Licensable Neuroscience Projects" by Windhover.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070608/NEF043LOGO )

Windhover Information's 2nd Annual Therapeutic Area Partnerships is the industry's most targeted and efficient partnering meeting for life science companies seeking partnerships in the top therapeutic areas: Oncology, Cardiovascular/Metabolic and Neuroscience. Decision-makers (business development and R & D) focusing on these therapeutic categories can meet to develop strategic alliances between their companies. For more information on the conference and speaking companies please go to http://www.tapartnerships.com .

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) is a biotechnology company engaged in developing breakthrough regenerative therapeutics to treat traumatic injuries and degenerative diseases. The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. Our energy and focus is reflected in several important initiatives. Cethrin(R) is a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury. Cethrin has demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a robust molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia and ADHD. ALTROPANE(R), the lead molecular imaging candidate, is in Phase III clinical trials for the diagnosis of Parkinson's disease. Alseres has research collaborations with Harvard Medical School and Children's Hospital Boston.

Contact: Sharon Correia

Director, Corporate Communications

scorreia@alseres.com

508-497-2360 ext. 224


'/>"/>
SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
2. Wisconsin firms to present at Cleantech venture capital event
3. New Sonic Foundry search engine finds words, phrases in video presentations
4. Lone Wisconsin firm to present at InvestMidwest
5. Sonic Foundry creates search engine for 7,000 expert video presentations
6. InvestMidWest calls for business presentations
7. Wicab to present BrainPort at Boston conference
8. Three more Wisconsin firms to present at venture forum
9. Six Wisconsin firms to present at BIO Mid-America VentureForum
10. New Health and Human Services representative for Midwest
11. Top 20 big pharmas represent majority of world pharma market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 21, 2017 , ... Functional near-infrared spectroscopy (fNIRS), an ... explored as a way to track the brain’s response to acute pain in adults ... cold pressor test ,” published today in the journal Neurophotonics , by ...
(Date:3/22/2017)... -- Personal Genome Diagnostics Inc. (PGDx) today announced an ... U.S. Department of Veterans Affairs (VA) that replaces ... new CancerSELECT ™ 125 test. CancerSELECT 125 ... that includes microsatellite instability status (MSI), a biomarker ... inhibitor immunotherapies. CancerSELECT 125 will be available to ...
(Date:3/20/2017)... ... March 20, 2017 , ... ... of endogenous hormones to regulate homeostasis via their cognate nuclear receptors. By ... adverse reproductive, neurological, proliferative, and immunological disorders. EDC exposure can occur directly, ...
(Date:3/20/2017)... ... March 20, 2017 , ... Charm Sciences, Inc. ... play system that counts Peel Plate microbial test colonies, stores plate images, exports ... unit has an internal computer, and is accurate within 10% of an experienced ...
Breaking Biology Technology:
(Date:3/2/2017)... 2, 2017 Australian stem cell and regenerative ... has signed an agreement with the Monash Lung Biology ... Discovery Institute and Department of Pharmacology at Monash University, ... preclinical study to support the use of Cymerus™ mesenchymal ... Asthma is a chronic, long term lung ...
(Date:2/27/2017)... Strategic Cyber Ventures , the industry,s first cybersecurity focused ... investment in  Polarity , the first commercial human memory-augmentation ... and is led by cybersecurity veterans Tom Kellermann ... , also a longtime cybersecurity veteran and founder of ... round of funding. This new funding will be used ...
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis ... Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen wurde ... um diese Prognose zu realisieren. ... Zu den Schwierigkeiten ... Mittel für die Biobank, die Implementierung Zeit sparender Technologien, ...
Breaking Biology News(10 mins):